GENMAB A/S (GNMSF:OTCMKTS)

$289.16 3.16 (1.1049%)

watchlist-icon
search-icon
Profile Icon

Most Recent Average Sentiment Analysis Score (0 to 100): 63

negative-sentiment
Negative [0, 35)
neutral-sentiment
Neutral [35, 65]
positive-sentiment
Positive (65, 100]
Visualize Sentiment Trendline

Analysed GENMAB A/S (GNMSF:OTCMKTS) News Sources

Capital Increase in Genmab as a Result of Employee Warrant Exercise

16-06-2026

yahoo.com

external link

VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026

18-06-2026

yahoo.com

external link

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival

29-06-2026

yahoo.com

external link

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

06-07-2026

yahoo.com

external link

Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?

08-07-2026

yahoo.com

external link

Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

13-07-2026

yahoo.com

external link

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026

15-07-2026

yahoo.com

external link

CoreWeave upgraded, IBM initiated: Wall Street's top analyst calls

22-07-2026

yahoo.com

external link

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

23-07-2026

yahoo.com

external link

AbbVie (ABBV) Could Be 3% Undervalued Following Epcoritamab Trial Setback

25-07-2026

yahoo.com

external link

GENMAB A/S (GNMSF:OTCMKTS) Sentiment Trend

0 25 50 75 100 55 85 58 75 93 87 76 4 23 78 16-06-2026 18-06-2026 29-06-2026 06-07-2026 08-07-2026 13-07-2026 15-07-2026 22-07-2026 23-07-2026 25-07-2026 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 Negative < 35 Neutral 35–65 Positive > 65 View FAQ

GENMAB A/S (GNMSF:OTCMKTS) FAQs

toggle

What is the current price of GENMAB A/S (GNMSF:OTCMKTS)?

The current price of GENMAB A/S (GNMSF:OTCMKTS) is $289.16.


toggle

GENMAB A/S (GNMSF:OTCMKTS) absolute price change since previous trading day?

The absolute price change of GENMAB A/S (GNMSF:OTCMKTS) since the previous trading day is $3.16.


toggle

GENMAB A/S (GNMSF:OTCMKTS) percentage price change since previous trading day?

The percentage price change of GENMAB A/S (GNMSF:OTCMKTS) since the previous trading day is 1.1049%.


toggle

What is the most recent average sentiment score for GENMAB A/S (GNMSF:OTCMKTS)?

The most recent average sentiment score for GENMAB A/S (GNMSF:OTCMKTS) is 63 out of 100.


toggle

What is the most recent average sentiment for GENMAB A/S (GNMSF:OTCMKTS)?

The most recent sentiment for GENMAB A/S (GNMSF:OTCMKTS) is .


SEC-8K** Filing Available For GENMAB A/S (GNMSF:OTCMKTS)

** material developments that could impact a company's financial condition or stock price.

Similar Securities People Also Ask

GNFTY (Genfit S.A. ADR)
NVZMF (Novonesis A S)
GNMLF (Genomma Lab International Sab DE Cv)

Author: MattELab

X Icon

GitHub Icon

MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.